🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  2. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  3. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  4. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  5. Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]

    Acadia Pharmaceuticals B.V.

    Autism Spectrum Disorder

    phase 2 small molecule active

    1 trial

  6. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  7. Placebo

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  8. Placebo

    Acadia Pharmaceuticals B.V.

    Anxiety

    phase 2 small molecule active

    1 trial

  9. Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy

    phase 2 small molecule active

    1 trial

  10. Placebo

    Alnylam Netherlands B.V.

    IgA Nephropathy (IgAN)

    phase 2 small molecule terminated

    1 trial

  11. Placebo matching BLU-808, tablet, BLU-808, BLU-808

    Blueprint Medicines (Netherlands) B.V.

    Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  12. RP-A501

    Rocket Pharmaceuticals B.V.

    Danon Disease

    phase 2 gene therapy active

    2 trials

  13. RP-L102

    Rocket Pharmaceuticals B.V.

    Fanconi Anemia Complementation Group A

    phase 2 mab active

    3 trials

  14. RP-L201

    Rocket Pharmaceuticals B.V.

    Leukocyte Adhesion Defect - Type I

    phase 2 mab completed

    2 trials

  15. RP-L301

    Rocket Pharmaceuticals B.V.

    Pyruvate Kinase Deficiency

    phase 2 mab on hold

    2 trials

  16. Revusiran

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  17. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  18. S-337395

    Shionogi B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  19. S-606001 matching placebo, S-606001

    Shionogi B.V.

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial

  20. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials

  21. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight

    phase 2 small molecule completed

    1 trial

  22. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  23. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight and Obesity

    phase 2 small molecule completed

    1 trial

  24. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Prader-Willi Syndrome

    phase 2 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources